IRIS
TRIPEPI, GIOVANNI LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 821
NA - Nord America 648
EU - Europa 329
SA - Sud America 213
AF - Africa 36
Continente sconosciuto - Info sul continente non disponibili 30
OC - Oceania 2
Totale 2.079
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 595
SG - Singapore 284
IT - Italia 158
CN - Cina 155
BR - Brasile 150
VN - Vietnam 135
HK - Hong Kong 59
BD - Bangladesh 53
DE - Germania 33
FR - Francia 30
FI - Finlandia 20
RU - Federazione Russa 20
KR - Corea 19
EC - Ecuador 18
MX - Messico 18
CA - Canada 17
GB - Regno Unito 17
AR - Argentina 15
IN - India 14
ID - Indonesia 13
IQ - Iraq 12
TR - Turchia 11
VE - Venezuela 11
UA - Ucraina 10
ZA - Sudafrica 10
PK - Pakistan 9
NL - Olanda 8
SA - Arabia Saudita 8
PH - Filippine 6
AE - Emirati Arabi Uniti 5
AT - Austria 5
CL - Cile 5
CZ - Repubblica Ceca 5
JP - Giappone 5
MA - Marocco 5
PY - Paraguay 5
UZ - Uzbekistan 5
EG - Egitto 4
ET - Etiopia 4
JM - Giamaica 4
JO - Giordania 4
KE - Kenya 4
PA - Panama 4
PL - Polonia 4
CO - Colombia 3
MY - Malesia 3
NP - Nepal 3
TN - Tunisia 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BE - Belgio 2
BG - Bulgaria 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
ES - Italia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
NI - Nicaragua 2
PE - Perù 2
RO - Romania 2
TH - Thailandia 2
TW - Taiwan 2
UY - Uruguay 2
AM - Armenia 1
AO - Angola 1
AU - Australia 1
AZ - Azerbaigian 1
BB - Barbados 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BY - Bielorussia 1
CH - Svizzera 1
CR - Costa Rica 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IE - Irlanda 1
IL - Israele 1
LY - Libia 1
MK - Macedonia 1
MZ - Mozambico 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
QA - Qatar 1
RS - Serbia 1
SC - Seychelles 1
SE - Svezia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
Totale 2.049
Salva come PNG Salva come JPEG
Città #
Singapore 117
San Jose 84
Ashburn 75
Florence 74
Council Bluffs 66
Hong Kong 58
Boardman 48
Ho Chi Minh City 40
Dallas 34
Beijing 32
Hefei 31
Los Angeles 27
Hanoi 22
New York 19
Santa Clara 19
Seoul 18
Shanghai 18
Munich 17
Lauterbourg 14
São Paulo 14
Helsinki 12
Noto 11
Sesto Fiorentino 11
Washington 10
Da Nang 9
Milan 9
Guayaquil 8
Portland 8
Quito 8
Haiphong 7
Mexico City 7
Montreal 7
Orem 7
Phoenix 7
Turku 7
Brasília 6
Brooklyn 6
Chicago 6
Biên Hòa 5
Addis Ababa 4
Amsterdam 4
Belo Horizonte 4
Bursa 4
Caracas 4
Chennai 4
Frankfurt am Main 4
Hillsboro 4
Nairobi 4
Naples 4
Ninh Bình 4
Rome 4
Tashkent 4
Thái Nguyên 4
Tokyo 4
Warsaw 4
Amman 3
Baghdad 3
Campinas 3
Caxias do Sul 3
Charlotte 3
Falkenstein 3
Kingston 3
Kyiv 3
Lahore 3
Las Vegas 3
London 3
Manaus 3
Omaha 3
Pretoria 3
Quảng Ngãi 3
Rio de Janeiro 3
Riyadh 3
San Francisco 3
Vienna 3
Winnipeg 3
Alexandria 2
Angeles City 2
Ankara 2
Atlanta 2
Bangkok 2
Bauru 2
Bishkek 2
Cairo 2
Can Tho 2
Casablanca 2
Catania 2
Columbus 2
Denver 2
Dhaka 2
Dubai 2
Duhok 2
Feira de Santana 2
Formosa 2
Guangzhou 2
Hangzhou 2
Hải Dương 2
Jeddah 2
Jinhua 2
Juiz de Fora 2
Jundiaí 2
Totale 1.152
Salva come PNG Salva come JPEG
Nome #
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 134
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 131
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 130
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 127
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 127
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 127
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 120
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 114
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 113
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 112
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 111
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 107
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 107
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 95
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 94
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 92
Long-term cognitive function changes with non-vitamin K oral anticoagulants in older patients with atrial fibrillation. A multicenter cohort study 91
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 48
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort 29
Skin Carotenoid Score as a Potential Early Biomarker of Metabolic Syndrome Risk in Adolescents 27
Relapse Despite MRD Negativity in Multiple Myeloma: Toward Integrated Risk Prediction 19
Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies 11
The Gut Microbiota in Hematologic Malignancies: Mechanisms, Clinical Associations, and Translational Opportunities 7
Rethinking On‐Target Off‐Tumor Toxicity as a Hematopoietic Continuum 2
Bridging Randomized Trial Efficacy and Real‐World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real‐World Evidence for Individualized Care 2
When MRD Is Not MRD: A Context-Dependent Interpretation in Clinical Decision-Making: A Context‐Dependent Interpretation in Clinical Decision‐Making 1
Multiple Myeloma and the Illusion of the Evidence Pyramid 1
Totale 2.079
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.105
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.105
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202328 0 0 0 0 0 0 14 0 0 3 11 0
2023/2024239 3 8 52 46 29 32 14 4 4 2 4 41
2024/2025399 9 32 8 25 24 24 8 12 70 41 40 106
2025/20261.289 133 66 83 74 197 98 147 59 127 141 83 81
2026/2027124 67 26 31 0 0 0 0 0 0 0 0 0
Totale 2.079